IMCR · Immunocore Holdings plc
$35.00
-0.77% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-65.1
Dividend yield
—
Beta
0.73
Avg volume
1M
Employees
1K
2D change
—
5D change
-4.90%
10D change
-3.40%
30D change
9.36%
60D change
16.89%
MTD change
6.70%
YTD change
-2.71%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMCR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-20
Latest call per bank · past 12 months
Jefferies
Hold$33.00
-5.7% vs priceMorgan Stanley
Equal-Weight$36.00
+2.9% vs priceWells Fargo
Overweight$60.00
+71.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-20 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 2026-04-14 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 2026-03-16 | Jefferies | Downgrade | Buy → Hold | $48.00 → $33.00 |
| 2026-02-26 | Needham | Maintains | Buy | $71.00 → $75.00 |
| 2026-02-04 | HC Wainwright & Co. | Reiterates | Buy | $100 |
| 2025-11-10 | Morgan Stanley | Maintains | Equal-Weight | $34.00 → $36.00 |
| 2025-10-31 | Wells Fargo | Initiates | Overweight | $0.00 → $60.00 |
| 2025-10-22 | HC Wainwright & Co. | Reiterates | Buy | $100 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.1% above the 50-day MA ($30.72).
- Price vs 200-day MA: Trading 3.1% above the 200-day MA ($32.49).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.08) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($27.79) and high ($40.22).
IMCR Price Chart
Loading chart for IMCR…
Fundamentals
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.